Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast

ConclusionsWe were able to validate our previously reported findings regarding the prognostic potential of myxoid periductal stroma in an independent DCIS patient cohort. A CRS based on nuclear grade, myxoid stromal architecture and stromal inflammation might facilitate discrimination of low risk from high risk patients. Consequently, the CRS may tailor adjuvant therapy. Future research should investigate whether radiotherapy can be safely omitted in patients with a low CRS.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research